gla-se
Vaccineexperimental
Gla, also called Glas (Γλας), was an important fortified site of the Mycenaean civilization, located in Boeotia, mainland Greece. Despite its impressive size, more than ten times larger than contemporary Athens or Tiryns, Gla is not mentioned in the Iliad, or perhaps is referred to by a name as yet unidentified. — Wikipedia
Clinical trial activity
36 trials · 53 clinical orgs · 0 marketing orgs
Phase 1
25
Phase 2
10
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2011 (NCT01154049)
Timeline
Indications
Studied for
- Carcinoma, Merkel Cell · Phase 1
- Colorectal Neoplasms · Phase 1
- Food Hypersensitivity · Phase 1
- Healthy Volunteers · Phase 1
- HIV Infections · Phase 1
- Influenza A Virus, H7N9 Subtype · Phase 1
- Influenza, Human · Phase 1
- Leishmaniasis · Phase 1
- Leishmaniasis, Visceral · Phase 1
- Leprosy · Phase 1/Phase 2
- Lymphoma, T-Cell, Cutaneous · Phase 2
- Malaria · Phase 1
- Respiratory Tract Diseases · Phase 2
- Respiratory Tract Infections · Phase 2
- RNA Virus Infections · Phase 2
- Sarcoma · Phase 1
- Schistosoma mansoni · Phase 2
- Schistosomiasis · Phase 2
- Schistosomiasis haematobia · Phase 2
- Schistosomiasis mansoni · Phase 2
- Tuberculosis · Phase 2
- Tuberculosis, Pulmonary · Phase 2
- Vaccination · Phase 2
- Virus Diseases · Phase 2
Mechanism of action
- UnclearImmunity, active
Unclear immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaGla ↗
Also known as
- gla
- gla
- gla-se
- leish-f3 + gla-se
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06714513 | Phase 1 | Dec 31, 2024 | Ajou University, Catholic University of Korea, Chung-Ang University, Quratis Inc., Yonsei University |
| NCT06670755 | N/A | Nov 30, 2024 | University of Oxford |
| NCT06205589 | Phase 2 | Oct 15, 2024 | Aurum Institute, National Institute of Allergy and Infectious Diseases (NIAID), University of Washington |
| NCT05999825 | Phase 2 | Sep 30, 2024 | Leiden University, Medical Research Council-UVRI Uganda Research Unit on AIDS, Texas Tech University |
| NCT05762393 | Phase 1 | Aug 1, 2023 | International Vaccine Institute |
| NCT05658614 | Phase 2 | Jul 1, 2022 | Biomedical Research Center EPLS, Oswaldo Cruz Foundation |
| NCT05292391 | Phase 1 | May 23, 2022 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT05182125 | Phase 1 | Nov 25, 2021 | Department of Health and Human Services, HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) |
| NCT04927585 | Phase 1 | Jul 8, 2021 | Harvard University, Immune Design, Worcester HIV Vaccine |
| NCT04607408 | Phase 1 | Nov 10, 2020 | Duke University, HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), University of the Witwatersrand |
| NCT03947437 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2019 | Immune Design, Oswaldo Cruz Foundation |
| NCT03742804 | Phase 2 | Jun 30, 2019 | Yale University |
| NCT03982121 | Phase 1 | Jun 4, 2019 | Institut Gustave Roussy |
| NCT03856996 | Phase 1 | May 23, 2019 | Emory University, National Institute of Allergy and Infectious Diseases (NIAID), Vanderbilt University |
| NCT03806699 | Phase 1 | Apr 2, 2019 | Quratis Inc. |
| NCT03799510 | Phase 2 | Dec 13, 2018 | Biomedical Research Center EPLS, Biomedical Research Center ESPOIR POUR LA SANTE, Immune Design, Orygen Biotecnologia SA, Oswaldo Cruz Foundation |
| NCT03722472 | Phase 1 | Oct 2, 2018 | Immune Design, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH) |
| NCT03330899 | Phase 1 | Sep 24, 2018 | Butantan Institute, University of Sao Paulo |
| NCT03806686 | Phase 2 | May 31, 2018 | Immune Design, Quratis Inc. |
| NCT03463135 | Phase 1 | May 7, 2018 | Sanofi |
Showing 20 of 36 trials
Page 1 / 2
Organizations
Research & Development (53)
53 organizations
Page 1 / 3